Use of erythropoietin for cardiovascular protection.
Bahlmann
Ferdinand H
FH
D043925:Angiogenesis Inducing Agents / Q000494:pharmacology*; D000818:Animals; D002465:Cell Movement / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D000068256:Darbepoetin alfa; D042783:Endothelial Cells / Q000187:drug effects* / Q000473:pathology; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000494:pharmacology; D006331:Heart Diseases / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D009206:Myocardium / Q000473:pathology; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D013234:Stem Cells / Q000187:drug effects* / Q000473:pathology; D016277:Ventricular Function, Left / Q000187:drug effects
D043925:Angiogenesis Inducing Agents; D004921:Erythropoietin; D000068256:Darbepoetin alfa